The company's average rating is Strong Buy from 3 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Artelo Biosciences market sentiment investors' perception of the future value of Artelo. Let us look at a few aspects of Artelo technical analysis.
Using predictive
technical analysis, we can analyze different prices and returns patterns and
diagnose historical swings to determine the real value of Artelo Biosciences. In general, sophisticated investors focus on analyzing Artelo Biosciences stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build Artelo Biosciences's daily price indicators and compare them against related drivers such as
momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional
technical analysis and
fundamental analysis, we attempt to find the most accurate representation of Artelo Biosciences's intrinsic value. In addition to deriving basic predictive indicators for Artelo Biosciences, many experienced traders also check how macroeconomic factors affect Artelo Biosciences price patterns. Please read more on our
technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed
many market ups and downs, anticipate that the market will even out over time. This tendency of Artelo Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Watch out for price decline
Please consider monitoring Artelo Biosciences on a daily basis if you are holding a position in it. Artelo Biosciences is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Artelo Biosciences stock to be traded above the $1 level to remain listed. If Artelo Biosciences stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How does Artelo Stands against Peers?
Analyzing Artelo Biosciences competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Artelo Biosciences across multiple sectors and
thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be. Check out
Artelo Biosciences Competition DetailsArtelo Biosciences Gross Profit
Artelo Biosciences Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Artelo Biosciences previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Artelo Biosciences Gross Profit growth over the last 10 years. Please check Artelo Biosciences'
gross profit and other
fundamental indicators for more details.
Closer look at Artelo Biosciences Mean Deviation
Artelo Biosciences has current Mean Deviation of 2.53. The mean deviation of the equity instrument is the first measure of the distances between each value of security historical prices and the mean. It gives us an idea of how spread out from the center the distribution of returns.
Mean Deviation is the average of the absolute values of the differences between price distribution numbers and their mean. Mean deviation of equity instrument with a lot of historical data is a biased estimator because the time horizon used in calculation will always be much smaller than the entire price history of the equity. The mean deviation is typically used as a measure of dispersion for small investment horizon, otherwise standard deviation is a better measure of dispersion.
Mean Deviation | = | SUM(RET DEV) N |
| = | 2.53 |
| SUM | = | Summation notation |
| RET DEV | = | Sum of return deviations of Artelo Biosciences |
| N | = | Number of calculation points for selected time horizon |
Let's now compare Artelo Biosciences Mean Deviation to its closest peers:
| ARTL | 2.5263141570247947 |
| AADI | 1.42 |
| ABCL | 2.37 |
| ABCM | 2.52 |
| ABOS | 3.9 |
Artelo Biosciences is projected to stay a bit over USD2.93 in March
Variance is down to 9.85. It may entail a possible volatility slide. Artelo Biosciences currently demonstrates below-average downside deviation. It has Information Ratio of 0.1 and Jensen Alpha of 0.31. However, we advise investors to further question Artelo Biosciences expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Artelo Biosciences' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Artelo Biosciences' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Bottom Line On Artelo Biosciences
Whereas other entities in the biotechnology industry are either recovering or due for a correction, Artelo may not be as strong as the others in terms of longer-term growth potentials. To conclude, as of the 27th of February 2023, we believe that at this point, Artelo Biosciences is
undervalued with
very low probability of distress within the next 2 years. Our present Buy-Hold-Sell recommendation on the company is
Strong Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Aina Ster is a Member of Macroaxis Editorial Board. Aina delivers weekly perspective on ongoing market and economic trends, analysis and tips from predictive analysis to forecasting across various financial instruments.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Aina Ster do not own shares of Artelo Biosciences. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com